Lynparza demonstrated overall survival benefit in Phase III PROfound trial for BRCA1/2 or ATM-mutated metastatic castration-resistant prostate cancer
24 April 2020 07:00 BST Lynparza demonstrated overall survival benefit in Phase III PROfound trialfor BRCA1/2 or ATM-mutated metastatic castration-resistant prostate cancer Only PARP inhibitor to improve overall survival vs. new hormonal agent treatments for this advanced prostate cancer population with high unmet needs AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced further positive results from the Phase III PROfound trial of Lynparza (olaparib) in men with metastatic castration-resistant